



Oncology Venture

Pres Release

Correction- Oncology Venture is streamlining its communications by publishing press releases in English only going forward.

In a press release regarding that the company has chosen to streamline its communications by publishing press releases in English only going forward, it was incorrectly stated that the information was published in accordance with the EU Market Abuse Regulation.

Hørsholm, November 12, 2019 – Oncology Venture A/S (“Oncology Venture”) today announces that the company has chosen to streamline its communications by publishing press releases in English only going forward.

For further information, please contact:

Henrik Moltke, CFO
E-mail: hm@oncologyventure.com
Telephone +45 53 63 96 37

About Oncology Venture A/S

Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, DRP®. The company has a mature portfolio of seven drug candidates, including compounds in the pre-registration stage.

The product portfolio includes: 2X-121 a PARP inhibitor in Phase 2 for Ovarian cancer; Dovitinib, for Renal Cell Carcinoma. Ixabepilone for the treatment of breast cancer. LiPlacis®, a liposomal formulation of cisplatin in Phase 2 trial for breast and prostate cancer 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; irofulven, in Phase 2 for prostate cancer; and APO010, an immuno-oncology product in Phase 1/2 for multiple myeloma.

About the Drug Response Predictor – DRP® Companion Diagnostic

Oncology Venture uses its multi gene DRP® to select those patients who by the genetic signature of their cancer are found to have a high likelihood of responding to the drug. By screening patients before treatment, the response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology. DRP® is based on messenger RNA from the patient's biopsies.

DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 29 out of 37 clinical studies that were examined.

The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs in the US.

Follow us on social media:

Facebook: <https://www.facebook.com/oncologyventure/>
LinkedIn: <https://www.linkedin.com/company/oncology-venture/>
Twitter: <https://twitter.com/OncologyVenture>

Learn more at oncologyventure.com.

Certified Adviser:

Svensk Kapitalmarknadsgranskning AB, Email: ca@skmg.se. Tel: +46 11 32 30 732

